Summary Results from the multicentre randomized trial of CHART (continuous, hyperfractionated, accelerated radiotherapy) in non-smallcell lung cancer (NSCLC) showed a significant increase in survival (P = 0.004) compared with conventional radiotherapy and a therapeutic benefit relative to late radiation-induced morbidity. However, 60% of patients died because of failure to control locoregional disease. These findings have stimulated interest in assessing the feasibility of dose escalation using a modified CHART schedule. Acute and late morbidity with a CHARTWEL (CHART WeekEnd Less) schedule of 54 Gy in 16 days was compared with that observed with 60 Gy in 18 days in patients with locally advanced NSCLC. The incidence and severity of dysphagia and of analgesia were scored using a semiquantitative clinical scale.
less; dose escalation: acute morbidity: late morbidity: non-small-cell lung cancer Non-small-cell lung cancer (NSCLC) is one of the most common causes of cancer-related deaths in the developed w-orld. Surgery is the treatment of choice but it is curative onlv in earls sta2e disease which. unfortunatelx. constitutes the minoritv of cases at the time of diagnosis. Patients with more adsvanced tumours apparently localized to the chest max be treated by radical radiotherapy. The outcome is. hosever. poor with 1-. 2-and 5-sear survival rates of 40%-. 15%e and 5c% respectively. and a median sursisal time of 10 months after a consentional 6-to 7-seek course of radiotherapy (Perez et al. 1987) . Results from a recent randomized radiotherapy trial in NSCLC show-ed that uncontrolled disease at the primary site was the principal cause of death in 60% of patients and was present at death in almost 90%7-of them (Saunders et al. 1997: unpublished data) . confirming, earlier post-mortem data (Saunders et al. 1984) . This suggests that much could be gained by improving, the manaaement of locoregional disease. Over the last ts o decades. attempts to improve local tumour control in NSCLC have included. among others. the use of oxx cen-mimetic radiosensitizers (Saunders et al. 1982 : Simpson et al. 1989 ). hi2h-LET radiation (Lindslev et al. 1996) and adjux ant chemotherapy any. impact on patient survisal.
Although the solume doubling time of NSCLC is slow, these tumours has e the potential to undergo ses eral cell doublings during the course of consentional radiotherapy. In a recent study of in visvo BUdR labelling, the median T of 28 tumour biopsies Vwas 7 days. but in some specimens it wvas as little as 1.6 days (Wilson. 1991) . Therefore. it wsould appear that locoregional response in NSCLC could be improsed by the use of treatment acceleration. CHART (continuous hyperfractionated accelerated radiotherapy ) is the most accelerated form of curatise radiotherapy and aims to reduce tumour clonogYen proliferation and. by using a dose per fraction <2 Gs. also to reduce the risk of late complications. After a successful pilot study of CHART at Mount Vernon hospital. Norths ood. UK. in NSCLC (Saunders and Dische. 1990 ). a multicentre randomized controlled trial w-as undertak-en betw.een 1990 and 1995. in which CHART was compared sith consventional radiotherapy in 563 patients. A recent update of the data has shown a 24% reduction in the relative risk of death w-ith CHART which translates into an absolute improvement at 1 y-ear of 8%-(63%-vs 55%-) and at 2 -ears of 9%-(29%-vs 20%): the differences are statistically significant (P = 0.004). There has been no indication of an increase in late morbiditv and. therefore. a significant therapeutic gain is achies ed with this schedule (Saunders et al. 1997) .
These results have stimulated interest in dose escalation w-ith CHART. To asoid shortening the interfraction inten-al and maintain 1323 The treatment was dixided into two phases. In all patients. except nine. the phase I v-olume included the mediastinum and primary7 tumour x ith a 1-cm margin. These patients had peripheral tumours and were irradiated with localized fields. which excluded the mediastinum. The mediastinum A as defined as extending from the suprasternal notch to 3 cm belowx the carina. The ipsilateral hilar nodes and paratracheal nodes were included but the contralateral hilum excluded. The phase H volume included the tumour and known nodal inx olvement with a 1-cm margin. Three or four fields w ere used throuahout treatment and correction x as made for transmission through the lung. Radiation doses were prescribed to the intersection point of the beams (Department of Health. 1978) .
The large volume received a dose of 37.5 Gy and the small volume 16.5 Gy escalating, to 22.5 Gy. Dose to the spinal cord dose wxas limited to a maximum of 44 Gy and that to the lunas. outside the planned target volume. to 20 Gy.
Radiotherapy wxas gixen on a 6/10-MeV linear accelerator. Table 1 ) was administered to patients treated with either CHARTWEL 54 Gy (0; n = 17) or CHARTWEL 60 Gy (A; n = 22). Solid symbols represent the mean (+ 1 s.e.m.) for each group achieved by increasing the number of fractions to 38, 39 and 40 respectively. Seventeen patients received 54 Gy, seven were treated to 57 Gy in 17 days, ten patients a dose of 58.5 Gy also in 17 days, whereas 30 patients received 60 Gy over 18 days. Two patients, both in the 60 Gy arm, were excluded from the analysis. In one of these patients, radiotherapy was interrupted after 28 Gy because of brain metastases and the other patient died less than 2 weeks after the end of treatment as a result of the primary tumour. The patients were seen weekly for 6 weeks from the start of treatment, then at 8 weeks and subsequently every 3 months up to 2 years, then twice a year up to 5 years and annually thereafter. Table  I summarizes the criteria used for quantitating early and late morbidity in oesophagus, lung and spinal cord. These scoring systems were developed in our department and have been used successfully in previous studies, including the CHART randomized trial (Dische et al, 1989) .
During treatment and until the acute reaction had settled, the severity of dysphagia and the medicines prescribed to ameliorate the symptoms were recorded. An arbitrary scale from 0 to 4 for dysphagia and from 0 to 3 for analgesia was used. The scores were recorded on weeks 1, 2, 3, 4, 5, 6 and 8 during or after radiotherapy. For the calculation of dysphagia and analgesia, the data from the 17 patients treated with 54 Gy, seven with 57 Gy, seven of the ten treated with 58.5 Gy and 22 of the 28 patients treated with 60 Gy were used. These were eliminated from the analysis of acute morbidity because the irradiation fields excluded the mediastinum. As there was no indication that acute or late reactions in the 57 and 58.5 Gy were higher than those seen with 54 Gy, comparisons in the paper are presented for CHARTWEL 54 Gy relative to CHARTWEL 60 Gy. Table 2 summarizes the staging and demographic details of these two groups.
For each patient, the individual weekly scores for dysphagia were plotted and an area under the curve (AUC), reflecting severity and duration of the acute reaction, was calculated by the trapezoid rule using a graphics package (Origin, Microcal). For clarity of presentation, a mean score as a function of time after treatment was obtained for each dose group. This procedure, however, has no strict statistical validity because the scale is nonparametric. A median value of dysphagia was calculated for each treatment and compared with the median score for analgesia given to patients during the same follow-up period. Table 3 summarizes median values of AUCs and analgesia in patients treated with CHARTWEL 54 or 60 Gy. To enable a statistical comparison between groups, for each patient the duration of dysphagia or analgesia was calculated at three cut-off points (Table 3 ). The significance in differences between treatments was estimated by carrying out Student's t-test using a standard statistical analysis computer package (JMP, SAS Institute).
At all subsequent follow-up attendances, radiation side-effects were monitored. Quantitation of late radiation-induced morbidity was made using the scoring criteria shown in Table 1 . At each follow-up, a chest radiograph was performed and a CT scan at 3-monthly intervals. Morbidity was analysed and statistical comparisons were made by computing actuarial disease-free intervals using the product-limit (Kaplan-Meier) method. Late oesophageal damage was taken as that occurring after the acute reactions had settled (i.e. after 3 months). Findings from clinical and radiological examinations were used to distinguish between the dysphagia due to tumour and that due to radiotherapy. Lung damage was diagnosed both by clinical and radiological examination. Acute pneumonitis was taken as the syndrome occurring during the first 6 months from first treatment, and late pulmonary toxicity as that evolving after this time. Two separate actuarial analyses were made: one which included patients with scores 1-3 and another which only considered scores 2 or 3 as positive events for either pneumonitis or late lung dysfunction (Table 1) .
Local tumour control was defined as being achieved when there was either complete disappearance of all abnormalities in the chest radiograph or CT scan, or when any residual abnormality observed at 6 months remained stable for a further 6 months or more. Patients who did not achieve local tumour control were defined as never being disease-free and were considered an event at time 0.
Overall survival was taken as the time from first treatment to death; patients still alive were censored at the time last seen. The response to treatment was assessed by calculating local tumour control and overall survival using the product-limit (KaplanMeier) method. Figure 1A shows mean dysphagia scores over the first 8 weeks after the start of radiotherapy in patients with carcinoma of the bronchus treated with either 54 Gy in 16 days or 60 Gy in 18 days. The reactions peaked on weeks 3 and 4 and, in general, the mean scores for dysphagia in patients treated with the higher dose were greater than that of patients receiving 54 Gy. This resulted in a higher median value for AUC for CHARTWEL 60 Gy and in a small, but significant, prolongation in the duration of mild and British Joumal of Cancer (1998) (Table 3 ). The severity of dysphagia can be monitored also by the degree of analgesia required to control symptoms. In this study, there was a strong correlation between the intensity and duration of dysphagia (i.e. the area under the curve) and the mean score of analgesia calculated for each patient (r = 0.8). On the whole, a less severe form and/or a shorter duration of analgesia was administered to patients treated with 54 Gy (Figure IB) , and there was a significant increase in the time during which either surface medication or non-narcotic analgesia were administered after CHARTWEL 60 Gy (P <0.01).
RESULTS
Even though actuarial analysis of dysphagia at 12 weeks after radiotherapy indicated a 12% and 5% incidence of radiationinduced oesophageal damage in patients treated with CHARTWEL 54 and 60 Gy respectively, this difference was not statistically significant (data not shown). There was no consequential necrosis in either of the two groups. The incidence of patients free of clinical symptoms of early pneumonitis and late lung morbidity are shown in Figure 2 using either the clinical (Figure 2A-C) or the radiological criteria ( Figure 2D ). Two separate analyses are presented: one for patients exhibiting any degree of dysfunction (scores 1-3 in Table 1 ) and another for patients presenting only the more severe symptoms (scores 2 or 3). At 6 months, just under 60% of patients treated with 54 Gy were pneumonitis-free compared with 69% in the 60 Gy arm (all scores). When the higher scores were used as cut-off points, 82% and 88% of patients were free of clinical signs of pulmonary complications. The difference in the incidence of acute radiation pneumonitis between the two schedules was not significant. There was no clinical evidence of moderate or severe late lung dysfunction, i.e. none of the patients presented a score of 2 or 3 (data not shown). However, if patients with mild symptoms not interfering with life style were considered as responders (i.e. score 1), there was a significant increase in the incidence of grade 1 pulmonary toxicity with CHARTWEL 60 Gy. Two years after radiotherapy, over 80% of these patients showed some degree of lung impairment, compared with a less than 10% incidence in those treated with CHARTWEL 54 Gy (P = 0.03; Figure 2C ). When the radiological assessment of lung damage was used for quantitating radiation-induced injury and considering only those patients with a score of 2 or 3 as responders, almost all presented evidence of damage in the irradiated volume, as would be expected ( Figure 2D ). In either of the two schedules, there have been no cases of L'Hermittes, radiation myelitis or of oesophageal strictures.
DISCUSSION
These data show that when the total radiation dose in a CHARTWEL schedule to NSCL carcinomas was increased from 54 Gy in 16 days to 60 Gy in 18 days, the acute oesophageal reactions were significantly enhanced. Although hardly any difference was observed in British Joumal of Cancer (1998) 78(10) Dose escalation using CHARTWEL in non-small-cell lung cancer 1327 However, the difficulty will lie in identifying an effective druc combination that does not compromise the therapeutic benefit of CHART and CHARTWEL regimes.
